Yingyu Chen

Dr. Yingyu Chen

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Hematology
Verified
Journal Article
Open access
PDF file
YCYingyu Chen
Yingyu Chen
JHJianda Hu
Jianda Hu
Nucleophosmin (NPM1) is an abundant nucleolar protein that is implicated in a variety of biological processes and in the pathogenesis of several human malignancies. For hematologic malignancies, approximately one-third of anaplastic large-cell non-Hodgkin’s lymphomas were found to express a fusion between NPM1 and the catalytic domain of anaplastic lymphoma receptor tyrosine kinase. About 50–60% of acute myeloid leukemia patients with normal karyotype carry NPM1 mutations, which are characterized by cytoplasmic dislocation of the NPM1 protein. Nevertheless, NPM1 is overexpressed in various hematologic and solid tumor malignancies. NPM1 overexpression is considered a prognostic marker of recurrence and progression of cancer. Thus, NPM1 abnormalities play a critical role in several types of hematologic malignancies. This has led to intense interest in the development of an NPM1 targeting strategy for cancer therapy. The aim of this review is to summarize present knowledge on NPM1 origin, pathogenesis, and therapeutic interventions in hematologic malignancies.

11 August 2017 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
YCYingyu Chen
Yingyu Chen
XLX. Luo
X. Luo
JSJ. A. Schroeder
J. A. Schroeder
JCJ. Chen
J. Chen
CBC. K. Baumgartner
C. K. Baumgartner
QSQ. Shi
Q. Shi
Essentials The immune response is a significant concern in gene therapy. Platelet‐targeted gene therapy can restore hemostasis and induce immune tolerance. CD4 T cell compartment is tolerized after platelet gene therapy. Preconditioning regimen affects immune tolerance induction in platelet gene therapy. Summary Background Immune responses are a major concern in gene therapy. Our previous studies demonstrated that platelet‐targeted factor VIII (FVIII) (2bF8) gene therapy together with in vivo drug selection of transduced cells can rescue the bleeding diathesis and induce immune tolerance in FVIII null mice. Objective To investigate whether non‐selectable 2bF8 lentiviral vector (LV ) for the induction of platelet‐FVIII expression is sufficient to induce immune tolerance and how immune tolerance is induced after 2bF8LV gene therapy. Methods Platelet‐FVIII expression was introduced by 2bF8LV transduction and transplantation. FVIII assays and tail bleeding tests were used to confirm the success of platelet gene therapy. Animals were challenged with rhF8 to explore if immune tolerance was induced after gene therapy. Treg cell analysis, T‐cell proliferation assay and memory B‐cell‐mediated ELISPOT assay were used to investigate the potential mechanisms of immune tolerance. Results We showed that platelet‐FVIII expression was sustained and the bleeding diathesis was restored in FVIII null mice after 2bF8LV gene therapy. None of the transduced recipients developed anti‐FVIII inhibitory antibodies in the groups preconditioned with 660 cG y irradiation or busulfan plus ATG treatment even after rhF8 challenge. Treg cells significantly increased in 2bF8LV ‐transduced recipients and the immune tolerance developed was transferable. CD 4+ T cells from treated animals failed to proliferate in response to rhF8 re‐stimulation, but memory B cells could differentiate into antibody secreting cells in 2bF8LV ‐transduced recipients. Conclusion 2bF8LV gene transfer without in vivo selection of manipulated cells can introduce immune tolerance in hemophilia A mice and this immune tolerance is CD 4+ T cell mediated.

19 August 2014 in International Journal of Oncology
Verified
Journal Article
Closed access
PDF file
YCYingyu Chen
Yingyu Chen
JLJing Li
Jing Li
JHJianda Hu
Jianda Hu
JZJing Zheng
Jing Zheng
ZZZhihong Zheng
Zhihong Zheng
MLMinhui Lin
Minhui Lin
Emodin, an extracted natural compound from the root and rhizome of Rheum palmatum L, has been shown to have multiple biological activities including anticancer functions in previous studies. In this study, we investigated the anti-leukemic activity of emodin alone or emodin in the presence all-trans retinoic acid (ATRA) in acute myeloid leukemia (AML) cells and the potential signaling pathway involved. We demonstrated that emodin could significantly enhance the sensitivity to ATRA and present additive differentiation-inducing effects in AML cell line NB4 cells and, especially, in NB4-derived ATRA-resistant MR2 cells. Further study showed that increasing dose of emodin could effectively induce growth inhibition and apoptotic effects in both cell lines as well as in primary leukemic cells from AML patients. Moreover, the apoptotic induction in AML cells was associated with the activation of caspase cascades involving caspase-9, caspase-3, and poly(ADP-ribose) polymerase (PARP) cleavage. In addition, leukemic cell response to emodin stimuli in vitro was observed through the decreased expression levels of Bcl-2 and retinoic acid receptor α (RARα). Importantly, emodin was demonstrated as a new inhibitor of PI3K/Akt in AML cells, even in primary AML cells. It inhibited Akt phosphoration (p-Akt) at Ser473 as efficiently as mTOR at Ser2448. Consistently, it exerted suppression effects on the phosphoration of mTOR downstream targets, 4E-BP1 and p70S6K. Taken together, these findings indicate that emodin might be developed as a promising anti-leukemic agent to improve the patient outcome in AML.

8 December 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
LLLiping Luo
Liping Luo
QZQiaoyun Zheng
Qiaoyun Zheng
ZCZhenyu Chen
Zhenyu Chen
MHMeijuan Huang
Meijuan Huang
LFLin Fu
Lin Fu
YCYingyu Chen
Yingyu Chen
The development of coagulation factor VIII (FVIII) inhibitory antibodies is a serious complication in hemophilia A (HA) patients after FVIII replacement therapy. Inhibitors render regular prophylaxis ineffective and increase the risk of morbidity and mortality. Immune tolerance induction (ITI) regimens have become the only clinically proven therapy for eradicating these inhibitors. However, this is a lengthy and costly strategy. For HA patients with high titer inhibitors, bypassing or new hemostatic agents must be used in clinical prophylaxis due to the ineffective ITI regimens. Since multiple genetic and environmental factors are involved in the pathogenesis of inhibitor generation, understanding the mechanisms by which inhibitors develop could help identify critical targets that can be exploited to prevent or eradicate inhibitors. In this review, we provide a comprehensive overview of the recent advances related to mechanistic insights into anti-FVIII antibody development and discuss novel therapeutic approaches for HA patients with inhibitors.

10 August 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
YCYingyu Chen
Yingyu Chen
DGDonghui Gan
Donghui Gan
QHQinghua Huang
Qinghua Huang
XLXiaofeng Luo
Xiaofeng Luo
DLDonghong Lin
Donghong Lin
JHJianda Hu
Jianda Hu
Background/Aims: Acute myeloid leukemia (AML) remains a hematologic malignancy with poor survival and a high risk of relapse, which is mainly caused by the emergence of multidrug resistance (MDR). The identification of novel agents to improve therapeutic strategies becomes important priority for AML treatment. It has been shown that emodin has therapeutic effects on many kinds of human malignant tumors. In this study, we investigated the anti-leukemia effects of emodin alone or in combination with cytarabine (Ara-C) on multidrug-resistant AML HL-60/ADR cells and in a mouse xenograft model of human highly tumorigenic AML HL-60/H3 cells. The underlying mechanism was also addressed. Methods: Cell viability after treatment was measured by MTT assay. The DNA fragmentation assay, Annexin V-PE/7-AAD, AO/EB staining, and electron microscopy were introduced to assess the apoptotic induction effects. Changes in protein expression in the Akt and ERK signaling pathways were determined by western blotting. In vivo antileukemia effects on HL-60/H3 xenograft model and overall mouse survival outcomes were further analyzed in this study. Results: Emodin dose-dependently induced growth inhibition and apoptotic effects in resistant HL-60/ADR cells in vitro as well as in the HL-60/H3 xenograft models in vivo. Moreover, emodin significantly enhanced chemosensitivity of AML cells to Ara-C, inhibited leukemic cell growth, and improved survival in the mouse xenograft model of AML. Dual targeting of Akt and ERK signaling pathways might contribute to the anti-leukemia effects on AML cells in vitro and in vivo. Conclusion: Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation.

24 September 2010 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CCChangbao Chen
Changbao Chen
HZHua Zhou
Hua Zhou
LXLanjun Xu
Lanjun Xu
XLXiaoguang Liu
Xiaoguang Liu
ZLZhongjun Liu
Zhongjun Liu
QMQingjun Ma
Qingjun Ma